Clinical Trial: A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06879041) titled 'A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer' on March 11.

Brief Summary: The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

Study Start Date: March 13

Study Type: INTERVENTIONAL

Condition: Metastatic Castration-Resistant Prostate Cancer

Intervention: DRUG: AZD2287

AZD2287 is administered through intravenous injection.

DRUG: AZD2275

AZD2275 is administered through intravenous infusion.

DRUG: AZD2284

AZD2284 is administered through intravenous injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: AstraZeneca...